Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Lescol XL

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Extended-release 80 mg tablet formulation of fluvastatin produced up to a 38% median decrease in low-density lipoprotein cholesterol in patients with dyslipidemia compared to Lescol 40 mg in Phase III clinical trials, the company said, announcing the Oct. 6 approval of the new tablet. "A 25% median decrease in triglycerides and a 13% mean increase in high-density lipoprotein cholesterol in patients with primary mixed dyslipidemia (Fredrickson Type IIb)" compared to Lescol 40 mg was also seen in the trials, the company reported. The NDA for the extended-release formulation was submitted Dec. 8, 199
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001209

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel